Condition: Malignant Neoplasm · Sponsor: Tyligand Pharmaceuticals (Suzhou) Limited
The study is a first-in-human (FIH), open-label, multi-center phase 1/2 study of TSN1611 in subjects with KRAS G12D mutant advanced solid tumors. This study will consist of a phase 1 dose escalation part and phase 2 dose expansion part. This study will evaluate the efficacy of TSN1611 at RP2D(s) through ORR using RECIST version 1.1, and determine and confirm the MTD/RP2D for TSN1611 in combination with cetuximab, in combination with cetuximab and mFOLFOX6, in combination with gemcitabine and albumin-bound paclitaxel in subjects with selected solid tumors.
This description comes directly from the study's public registry record.
Tyligand Clinical Trial Info · +86 021-50720081 · clinical_trial@tyligand.com
Always discuss trial participation with your own doctor first.
| MD Anderson Cancer Center | Houston, Texas, United States | Recruiting |
| NEXT Oncology | San Antonio, Texas, United States | Recruiting |
| NEXT Virginia | Fairfax, Virginia, United States | Recruiting |
| Anhui Provincial Cancer Hospital | Hefei, Anhui, China | Recruiting |
| Beijing Cancer Hospital | Beijing, Beijing Municipality, China | Recruiting |
| The First Affiliated Hospital of Guangzhou Medical University | Guangzhou, Guangdong, China | Recruiting |
| Hubei Cancer Hospital | Wuhan, Hubei, China | Recruiting |
| Hunan Cancer Hospital | Changsha, Hunan, China | Recruiting |
| The First Affiliated Hospital of Nanchang University - Donghu District | Nanchang, Jiang, China | Recruiting |
| Linyi Cancer Hospital | Linyi, Shandong, China | Recruiting |
| Shanghai Tenth People's Hospital | Shanghai, Shanghai Municipality, China | Recruiting |
| West China Hospital, Sichuan University | Chengdu, Sichuan, China | Recruiting |
+ 7 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06385925